Lucatumumab

N/A

Report date: 2023/05/05 17:37:06

Base Information

Drug NameLucatumumab
Drug Alias Name鲁卡木单抗HCD-122CHIR-12.12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsMultiple MyelomaLymphoma, FollicularLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgXoma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgXoma (Us) Llc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, FollicularLymphoma, Non-Hodgkin +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG